Evaluation of individual clinical outcomes in medical interventions;Medición del impacto de intervenciones médicas a nivel individual

Revista de Investigacion Clinica

Volumn 49, Issue 5, 1997, Pages 379-386

  López Jiménez, Francisco ^a,b   Rohde, Luis Eduardo P ^a,b   Ponce de León Rosales, Samuel ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Effectiveness; Quality of life; Randomized clinical trial; Side effects; Therapy

Indexed keywords

ARTICLE; CLINICAL TRIAL; EPIDEMIOLOGY; HOSPITALIZATION; HUMAN; METHODOLOGY; PATIENT; PATIENT ATTITUDE; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME;

CLINICAL TRIALS; HUMANS; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENTS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; SAMPLING STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0141827841     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. López-Jiménez F, Luna-Jiménez MA. Tratamiento optimo. Lo que se pierde al no efectuarse. Rev Invest Clin 1997; 49:145-50.
2. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327:669-77.
3. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program (SHEP). JAMA 1991; 265:3255-64.
4. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy.I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308:81-106.
5. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge heart antioxidant study (CHAOS). Lancet 1996; 347:781-6.
6. Lara-Muñoz MC, León SP, De la Fuente JR. Conceptualización y medición de la calidad de vida de pacientes con cáncer. Rev Invest Clin 1996; 47:315-27.
7. Elmore JG, Wells CK, Lee CH, Howard DH, Feinstein AR. Variability in radiologists' interpretations of mammograms. N Engl J Med 1994; 331:1493-9.
8. Blackburn H, Blomgvist G, Freiman A. The exercise electrocardiogram: differences in interpretation. Report of a technical group on exercise electrocardiography. Am J Cardiol 1968; 21:871-9.
9. Arista-Nasr J, Cortés E, Keirns C, Hatchett A, Loria A. Diagnostic concordancy in biopsies of deceptive prostatic carcinoma. Rev Invest Clin 1995; 48:289-96.
10. Braunwald E. Valvular heart disease. En Braunwald E, ed. Heart disease. A textbook of cardiovascular disease. Philadelphia: WB Saunders; 1996:1007-76.
11. Stevenson R, Ranjadayalan K, Wilinson P, Roberts, Timis AD. Short and long-term prognosis of acute myocardial infarction since introduction of thrombolysis. BMJ 1993; 307:349-53.
12. Sackett DL. A primer on the precision and accuracy of the clinical examination. JAMA 1992; 267:2638-44.
13. Wilkin D, Hallan L Doggett MA. Methods of measurement. En: Wilkin D, Hallan L, Doggett MA, eds. Measures of need and outcome for primary health care. Oxford: Oxford University Press; 1992:20-40.
14. Greenfield S, Nelson EC. Recent development and future issues in the use of health status assessment measure in clinical settings. Medical Care 1992; 30:MS23-41.
15. Greenfield S. The state of outcome research: are we on target? N Engl J Med 1989; 320:1142-3.
16. Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Medical Care 1989; 27:S217-32.
17. Deyo RA, Patrick DL. Barriers to the use of health status measures in clinical investigation, patient care, and policy research. Medical Care 1989; 27:S254-68.
18. GISSI Investigators. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1:397-401.
19. ISIS-2 Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither, among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; II:349-60.
20. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Int Med 1992; 116:78-84.
21. Yusuf S, Wittes J, Probstfield J. Evaluating effects of treatment in subgroups of patients within a clinical trial: the case of non-Q-wave myocardial infarction and beta-blockers. Am J Cardiol 1990; 66:220-2.
22. Guyatt GH, Keller JL, Jaeschke R. Clinical usefulness of N-of-1 randomized control trials: three years experience. Ann Int Med 1990; 112:293-9.
23. Sackett DL, Haynes RB, Guyatt GH, Tugwell P. Deciding on the best therapy. En: Clinical Epidemiology: a basic science for clinical medicine. Boston: Little Brown; 1991:187-248.